Market Wrap Week 21: Big Winners in Health and Tech, Guidance Cut Hits Brambles

AnteoTech (ASX:ADO) topped the board with a weekly gain of 50.00% after it said its silicon anode material worked well in commercial drone battery cells. Investors cared because better battery performance can make a small technology company easier to sell to real customers. Imugene (ASX:IMU) climbed 36.84% after early cancer trial data showed a strong response rate. Close the Loop (ASX:CLG) added 34.78% after selling a business unit, cutting debt and giving a profit target for next year. On the downside, Brambles (ASX:BXB) dropped 22.58% after trimming its profit outlook, while American Tungsten & Antimony (ASX:AT4) fell 22.50% even after raising capital and securing a tax credit.

Capital raises and deal activity stayed busy

Mergers, takeovers and placements kept coming. Australian Strategic Materials (ASX:ASM) moved closer to a shareholder vote on Energy Fuels' takeover, with the implied offer pitched at A$1.63 to A$1.93 a share. SDI Limited (ASX:SDI) also advanced its own takeover process, with the court approving a shareholder meeting for the A$1.40 a share cash offer. GenusPlus (ASX:GNP) launched a A$200 million placement to help fund its A$400 million MPC Kinetic deal. Electro Optic Systems (ASX:EOS) raised fresh money for the MARSS acquisition and defence expansion. Buyers stuck with EOS after it came back on screen, which suggests investors accepted the dilution because they expect the larger business to win more work. Arafura Rare Earths (ASX:ARU) was one of the busiest names. It approved development of the Nolans project and then moved to close its equity funding gap with a A$350 million placement and a A$25 million share purchase plan. Investors care because this shifts the project from plans on paper to construction funding. That does not remove risk. It does mean the next test is whether construction starts on time in September 2026.

Resources names moved on money, mine plans and drill news

Gold, rare earths and battery minerals produced a long list of announcements. Geopacific Resources (ASX:GPR) updated its Woodlark gold study with a bigger resource, a new ore reserve and strong project economics. Challenger Gold (ASX:CEL) published a pre-feasibility study for Hualilan with a large net present value, which is a simple estimate of what the project could be worth in today’s money. Yet the share price still fell for the week, and the stock slid further after reopening. That tells you some holders likely sold into the news rather than wait for the next funding and development steps. Elsewhere, WA1 Resources (ASX:WA1) expanded the indicated part of its niobium resource at Luni and said it still had A$131 million in cash. Midas Minerals (ASX:MM1) reported strong copper-silver drilling in Namibia. Saturn Metals (ASX:STN) rose after fresh drilling supported a coming resource upgrade at Apollo Hill. Some smaller explorers saw the opposite pattern. Early gains in names such as Ballymore Resources (ASX:BMR) and Locksley Resources (ASX:LKY) evaporated after trading resumed. In plain English, traders chased the first move, then sellers came in and pushed the stocks back down.

Healthcare and tech buyers rewarded clearer progress

Healthcare names rose when the news was easy to understand. OncoSil Medical (ASX:OSL) jumped after winning Australian approval for its pancreatic cancer device. 4DMedical (ASX:4DX) pointed to clinical data showing better patient selection for lung surgery, though its shares still fell over the week. Vitasora (ASX:VHL) surged 27.27% after launching its own patient management software and saying this should cut software costs by more than 90%. Investors liked the direct link between a new system and lower spending. Software and platform companies also had a decent week. TechnologyOne (ASX:TNE) posted record half-year profit and recurring revenue, then reaffirmed guidance. Vista Group (ASX:VGL) won a six-year cloud deal with Cinépolis Mexico. Serko (ASX:SKO) lifted income and launched a US beta for its AI travel tool. Catapult Sports (ASX:CAT) rallied 21.43% after reporting strong revenue and EBITDA growth, even though it still posted a net loss. Investors looked through the loss because much of the damage came from acquisition costs and non-cash items, which are accounting charges rather than money leaving the bank that day.

Results season still punished disappointment

Not every update was rewarded. Brambles cut profit growth guidance after repair bottlenecks in the United States knocked about US$60 million from earnings. That was a clear reason for the sell-off: investors now expect less profit than they did a week ago. Gentrack (ASX:GTK) slid after flat revenue and a sharp EBITDA drop. Guzman y Gomez (ASX:GYG) still rose for the week even as it shut its US restaurants, because investors seemed to prefer a clean exit from a weak business rather than more losses. Across the broader list, strong numbers helped companies such as ALS (ASX:ALQ), AFT Pharmaceuticals (ASX:AFP), Smartgroup (ASX:SIQ), Ventia (ASX:VNT), Australian Agricultural Company (ASX:AAC) and Brisbane Broncos (ASX:BBL). The common thread was simple. Investors paid up when companies either grew profit, locked in recurring sales, or returned cash through dividends and buy-backs. They sold when guidance fell, when projects still needed large amounts of money, or when a reopening jump did not attract enough follow-up buying.